0.00
price down icon100.00%   -0.0941
 
loading
Schlusskurs vom Vortag:
$0.0941
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$5.67M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-31.59M
KGV:
0.00
EPS:
-2.61
Netto-Cashflow:
$-26.75M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$1.72

Palatin Technologies Inc. Stock (PTN) Company Profile

Name
Firmenname
Palatin Technologies Inc.
Name
Telefon
609-495-2200
Name
Adresse
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Name
Mitarbeiter
19
Name
Twitter
@PalatinTech
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
PTN's Discussions on Twitter

Vergleichen Sie PTN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PTN
Palatin Technologies Inc.
0.00 5.67M 7.10M -31.59M -26.75M -2.61
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2015-06-05 Bestätigt Canaccord Genuity Buy
2015-01-12 Bestätigt ROTH Capital Buy
2012-05-23 Eingeleitet Noble Financial Buy
2007-01-23 Eingeleitet Next Generation Buy

Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten

pulisher
Jul 29, 2025

Palatin Technologies Stockholders Approve Key Governance Changes - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Palatin Technologies shareholders approve reverse stock split and board elections - Investing.com

Jul 29, 2025
pulisher
Jul 24, 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - ADVFN Brasil

Jul 24, 2025
pulisher
Jul 16, 2025

Palatin Technologies reports efficacy of PL-7737 in obesity model - BioWorld MedTech

Jul 16, 2025
pulisher
Jul 16, 2025

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity - The Malaysian Reserve

Jul 16, 2025
pulisher
Jul 15, 2025

Palatin announces positive preclinical efficacy data for oral MC4R agonist PL7737 in animal model of obesity - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Breakthrough Oral Weight Loss Drug Achieves 15% Reduction When Combined with Tirzepatide in Just 4 Days - Stock Titan

Jul 15, 2025
pulisher
Jul 09, 2025

Palatin Technologies receives NYSE American delisting notice, appeals decision By Investing.com - Investing.com Nigeria

Jul 09, 2025
pulisher
Jul 09, 2025

Palatin Technologies receives NYSE American delisting notice, appeals decision - Investing.com Australia

Jul 09, 2025
pulisher
Jun 20, 2025

Palatin Technologies Announces Closing of Reduced Public Offering (PR Newswire) - Aktiellt

Jun 20, 2025
pulisher
Jun 13, 2025

Palatin Technologies Raises $340K in Private Placement - TipRanks

Jun 13, 2025
pulisher
May 27, 2025

Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus

May 27, 2025
pulisher
May 25, 2025

Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN

May 25, 2025
pulisher
May 20, 2025

Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World

May 20, 2025
pulisher
May 15, 2025

Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail

May 15, 2025
pulisher
May 15, 2025

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Palatin's New Obesity Drug Shows 4.4% Weight Loss When Combined With Popular GLP-1 Treatment - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com UK

May 13, 2025
pulisher
May 12, 2025

Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com

May 12, 2025
pulisher
May 10, 2025

Palatin reveals potential diabetic retinopathy treatments - Investing.com

May 10, 2025
pulisher
May 10, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India

May 10, 2025
pulisher
May 09, 2025

Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Two new option listings and two option delistings on May 9th - TipRanks

May 09, 2025
pulisher
May 09, 2025

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN

May 09, 2025
pulisher
May 09, 2025

Palatin Technologies (PTNT): A High-Risk Gamble Amid Financial Strains and Regulatory Setbacks - AInvest

May 09, 2025
pulisher
May 09, 2025

Palatin Technologies Announces Closing of Reduced Public Offering - Morningstar

May 09, 2025
pulisher
May 08, 2025

Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve

May 08, 2025
pulisher
May 08, 2025

Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard

May 08, 2025
pulisher
May 07, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Nigeria

May 07, 2025

Finanzdaten der Palatin Technologies Inc.-Aktie (PTN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Kapitalisierung:     |  Volumen (24h):